Concerns regarding SARS-CoV-2 JN.1 mutations should be raised

• Main Authors: Roney, Miah, Huq, A. K. M. Moyeenul, Mohd Fadhlizil Fasihi, Mohd Aluwi
• Format: Article
• Language: English
• Published: Springer Nature 2024
• Subjects: HD Industries. Land use. Labor; RZ Other systems of medicine
• Online Access: http://umpir.ump.edu.my/id/eprint/41715/1/The%20importance%20of%20in-silico%20studies%20in%20drug%20discovery.pdf; http://umpir.ump.edu.my/id/eprint/41715/; https://doi.org/10.1186/s42269-024-01207-0

JN.1 is a new variant of SARS-CoV-2 which is a subvariant of Omicron (BA.2.86) was first discovered in the USA in September 2023. The virus’s capacity to spread and elude the immune system may be impacted by a single alteration in the spike protein, which serves as its distinguishing feature. JN.1 has been classified as an interesting variety by the World Health Organisation. JN.1 might lead to a rise in infections, or its possible influence on public health is yet premature. Current immunisations, examinations, and therapies are still anticipated to combat JN.1.